Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

Antibe Therapeutics Inc(Pre-Merger) > Did you think 5x Liver Enzymes is Serious?
View:
Post by mstrmnd on Aug 03, 2021 7:22pm

Did you think 5x Liver Enzymes is Serious?

It's not...especially when higher doses are safe, therefore it's not dose-dependent

If up to 10% of patients on NSAIDS can have liver enzyme elevation normally, then we would expect at least 4 participants from the 42 person AME to have some degree of liver enzyme elevation...

Once everyone starts selling, can't stop irrational behaviour particularly when fear sets in...

New Buyers - Do your own DD - GLTA
Comment by RalphRalph on Aug 03, 2021 7:32pm
It's serious in the sense that it's going to delay Phase 3 and potentially alter their dosing strategy. It also undoubtedly has a negative impact on investor confidence, and certainly doesn't help the company negotiating position with big Pharma.  It also creates a significant amount of uncertainty about numerous aspects of the path forward
Comment by MasterAlgae on Aug 03, 2021 7:55pm
It is incredibly serious. It is 500% higher than normal. Even if it is alcohol related that is a major danger for this arthritis drug.   The entire pipeline is all hydrogen sulphide...   The press release said that further research is warranted on the formulation of the drug. That's Serious.   "these findings indicate that further research is warranted with ...more  
Comment by mstrmnd on Aug 03, 2021 8:56pm
This company is super defensive and ultra-low risk given Dan's legal background and fear mongering.  That's why he needs to go asap imho - his response to anything out of the ordinary is predictable and protects his own interests above all.  Cover himself right?  Screw the company.  To your points: 1. 5x increase in liver enzymes in 3 participants when baseline ...more  
Comment by AntibeTrash on Aug 03, 2021 9:03pm
This post has been removed in accordance with Community Policy
Comment by mstrmnd on Aug 03, 2021 9:05pm
This post has been removed in accordance with Community Policy
Comment by rixpix on Aug 03, 2021 10:08pm
I can never understand how some people can take so much pleasure in other people's misfortunes. SMH!!!  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse